Iskidrop

Nimodipine, the active ingredient in Iskidrop, is a calcium channel blocker presented as an oral formulation for oral use. It is employed to prevent cerebral vasospasm in patients who have experienced a subarachnoid hemorrhage. By selectively targeting L‑type calcium channels in cerebral vessels, it helps maintain adequate blood flow during the critical post‑hemorrhage period.

GNH USA supplies Iskidrop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU GMP standards and provides regulatory documentation to support global distribution.

Nimodipine is a cerebral vasodilator used in the management of vascular complications following subarachnoid hemorrhage.

- Subarachnoid hemorrhage (SAH): prevention of cerebral vasospasm after SAH. - Cerebral vasospasm: reduction of vasospasm severity in patients with SAH. - Neurosurgical procedures: prophylactic vasodilation to support cerebral perfusion during postoperative recovery.

Nimodipine may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate. - Dizziness or light‑headedness. - Nausea or vomiting. - Flushing or warmth sensation. - Hypotension: transient blood pressure drop. - Peripheral edema: mild swelling of ankles.

Serious or Rare Side Effects: - Severe hypotension: marked blood pressure reduction. - Cardiac arrhythmias: irregular heart rhythm. - Hepatotoxicity: elevated liver enzymes. - Allergic reactions: rash, pruritus, or anaphylaxis. - Thrombocytopenia: low platelet count.

When prescribing Nimodipine, clinicians should consider several safety measures to minimize risk.

- Cardiovascular monitoring: observe blood pressure and heart rate during initiation. - Hepatic function: assess liver enzymes before and during therapy. - Concomitant vasodilators: avoid simultaneous use with other potent vasodilators. - Renal impairment: adjust use in patients with severe renal dysfunction. - Pregnancy and lactation: use only if potential benefit justifies potential risk. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in original container.

Nimodipine can alter the pharmacokinetics or pharmacodynamics of several medicines; interactions are grouped by clinical significance.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase Nimodipine plasma levels. - Simultaneous use with other calcium channel blockers: risk of additive hypotension. - Nitrates: excessive vasodilation leading to severe hypotension.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce effectiveness. - Beta‑blockers: may enhance bradycardia. - Diuretics: may potentiate blood pressure lowering. - Anticoagulants: monitor for increased bleeding risk due to hypotension‑related falls.